BVAXF — BioVaxys Technology Corp.

OTC · Unknown · Unknown · CIK 1882559 ·
Last close
$0.18
Market Cap
$7.31M
52W High
$0.18
52W Low
$0.02
ADV30
110,550
Next earnings
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. Further, the company operates HapTenix Platform, a vaccine platform based on the established immunological concept that modifies surface proteins with haptens and T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies triggered by exposure to peanut/tree nuts or eggs and Adiverna LLC to develop mRNA-based Rabies, Leptospirosis, Feline Infectious Peritonitis (FIV) and other mRNA-based vaccines for companion animal veterinary applications. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Apr 2025 0 -1,290,159 -1,316,689 1,100,321 4,309 3,831,367
Jan 2025 0 -1,205,557 -1,070,198 1,281,310 157,415 3,024,088
Oct 2024 0 -1,499,245 -2,743,983 1,300,764 211,806 3,220,886

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,916,300
Investing CF
$0
Financing CF
$2,483,685
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$0.00
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-33,637,271
Inventory
Receivables
$470,276
ST Investments
EBIT TTM
$-3,994,961
Pretax Income TTM
$-5,130,870
Interest Exp TTM
Analysts

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Oct 2024 0 -3,295,516 -3,954,781 1,300,764 3,220,886 -1,862,237
Oct 2023 0 -6,453,188 -7,687,317 113,478 3,485,539 -1,054,849
Oct 2022 0 -4,081,793 -11,727,444 865,564 1,639,096 -1,574,609

News headlines (Yahoo Finance, 1h cache)

BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
2026-03-10 12:00 · Yahoo
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
2026-01-29 16:55 · Yahoo
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Ca
2026-01-20 13:00 · Yahoo
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
2026-01-08 13:00 · Yahoo
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
2025-12-17 13:00 · Yahoo
BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
2025-11-19 20:41 · Yahoo
BioVaxys Announces Extension of Life Offering Closing Date
2025-11-11 20:23 · Yahoo
BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
2025-10-30 20:54 · Yahoo
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
2025-10-28 11:00 · Yahoo
BioVaxys Technology Announces Conversion of Debentures
2025-10-22 11:44 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.